Loading...
•
Jun 30
Esperion Q2 2025 Earnings Report
Esperion reported strong second quarter 2025 financial results with significant revenue growth and achieved its first quarter of operating income from ongoing business.
Key Takeaways
Esperion delivered robust second quarter 2025 results, with total revenue increasing 12% year-over-year to $82.4 million, driven by a 42% surge in U.S. net product revenue. The company achieved its first quarter of operating income from ongoing business and expects sustainable profitability starting in Q1 2026. Key accomplishments include settlement agreements protecting intellectual property until 2040 and continued expansion of market access for its therapies.
Total revenue for Q2 2025 increased by 12% year-over-year to $82.4 million.
U.S. net product revenue grew significantly by 42% year-over-year to $40.3 million.
The company achieved its first quarter of operating income from ongoing business, reaching $15.0 million.
Settlement agreements were reached with three ANDA filers, preventing generic versions of NEXLETOL® until 2040.
Esperion
Esperion
Esperion Revenue by Segment
Revenue by Segment
U.S. Net Product Revenue
CapyFin.comCollaboration Revenue
CapyFin.com Forward Guidance
Esperion reiterates its full-year 2025 operating expense guidance and now expects to achieve sustainable profitability starting in the first quarter of 2026.
Positive Outlook
- Expects sustainable profitability beginning in Q1 2026.
- Otsuka Pharmaceutical Co., Ltd. (Japan partner) on track for expected approval and National Health Insurance pricing in H2 2025.
- Health Canada market approval for NEXLETOL and NEXLIZET expected in Q4 2025.
- Neopharm Israel partner on track for market approval of NEXLETOL and NEXLIZET in H1 2026.
- CSL Seqirus (Australia/New Zealand partner) expects market approval in Q4 2026.
Challenges Ahead
- Full year 2025 operating expenses are expected to be in the range of $215 million to $235 million.
- Approximately $15 million of the operating expenses are non-cash expenses related to stock compensation.
- No other specific negative forward guidance was provided in the report.